Emtricitabine (FTC, Emtriva)

The Basics | Research

Overview

Prescribing Information for Emtricitabine (FTC, Emtriva) (PDF) (November 2011)
From Gilead Sciences, Inc.
Labeling Changes for Emtriva (September 28, 2005)
Specific modifications since the label was last updated are highlighted.
From U.S. Food and Drug Administration
Approval of Emtriva for Treating HIV (July 2, 2003)
From U.S. Food and Drug Administration
FTC Has Been Approved: What Now? (July 2003)
An analysis of what we know so far -- and what we have yet to learn.
In TAGline, from Treatment Action Group
Separated at Birth: 3TC and FTC (July 2003)
A quick comparison of molecular structures.
In TAGline, from Treatment Action Group

Research & News

Switching to Rilpivirine/Tenofovir/FTC Fixed-Dose Combination From Boosted-PI Regimen: SPIRIT Study Draws the Line at 24 Weeks (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Prospective Randomized Trial of Emtricitabine Versus Lamivudine Short-Term Monotherapy in Human Immunodeficiency Virus-Infected Patients
In Journal of Infectious Diseases
Gilead and Tibotec Agree on New Single-Tablet Regimen (November 23, 2011)
In Positively Aware, from Test Positive Aware Network
Gilead and J&J Expand HIV Cocktail Partnership (November 16, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Gilead Raises Prices of HIV Drugs, AHF Speaks Out Against Price Hike (April 4, 2011)
In Bloomberg Businessweek
Emtricitabine and Lamivudine May Be Similar, but Their Resistance Profiles Differ in Important Ways (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
Emtriva: New Pediatric Formulation and Labeling Changes (September 28, 2005)
From U.S. Food and Drug Administration
Gilead, Royalty Pharma to Pay Emory University $525 Million for Rights to Emtricitabine (July 19, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
No Difference Seen in Resistance Profiles of Emtricitabine and Lamivudine (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration

VIEW ALL ARTICLES

MOST VIEWED ARTICLES

	HIV Management Today: Mental Health & HIV, the Uncharted Territory
	CROI 2013: Research on Aging and HIV (Video)
	Danish Study Targets HIV Reservoir, in Latest Search for HIV Cure
	PrEP Failures and Successes: One Study Whose Impact Will Last Well Beyond CROI 2013
	10 Top Studies Whose Impact Will Last Well Beyond CROI 2013
	HIV Opportunistic Infection Guidelines Updated

More Most Viewed Articles

TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.